Portola Pharmaceuticals CEO Scott Garland receives $5.8M in 2018
Portola Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 19, 2019
Portola Pharmaceuticals reported fiscal year 2018 executive compensation information on April 19, 2019.
In 2018, seven executives at Portola Pharmaceuticals received on average a compensation package of $3.7M, a 17% increase compared to previous year.
Scott Garland, Chief Executive Officer, received $5.8M in total. 50% of Garland's compensation, or $2.9M, was in option awards. Garland also received $200K in bonus, $70K in non-equity incentive plan, $145K in salary, $2.5M in stock awards, as well as $3.1K in other compensation.
William Lis, Chief Executive Officer, received a compensation package of $5.3M, which increased by 8% compared to previous year. 57% of the compensation package, or $3M, was in option awards.
John B. Moriarty, Jr., General Counsel, earned $4.3M in 2018.
Glenn Brame, Executive Vice President, Chief Technical Operations Officer, received $3.2M in 2018.
Ernie Meyer, Chief Human Resources Officer, earned $2.8M in 2018.
Mardi C. Dier, Executive Vice President, Chief Financial and Business Officer, received $2.5M in 2018, which increases by 2% compared to 2017.
John T. Curnutte, Executive Vice President, Research and Development, earned $2.2M in 2018, a 3% increase compared to previous year.
Related executives
Scott Garland
Portola Pharmaceuticals
Chief Executive Officer
Mardi Dier
Portola Pharmaceuticals
Executive Vice President, Chief Financial and Business Officer
John Curnutte
Portola Pharmaceuticals
Executive Vice President, Research and Development
John Moriarty
Portola Pharmaceuticals
General Counsel
Glenn Brame
Portola Pharmaceuticals
Executive Vice President, Chief Technical Operations Officer
Ernie Meyer
Portola Pharmaceuticals
Chief Human Resources Officer
William Lis
Portola Pharmaceuticals